On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Deep-pocketed investors have adopted a bearish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.

Avidity Biosciences stock surges on expansion of pipeline targeting rare genetic cardiomyopathies and improvements in siRNA ...

In trading on Monday, shares of Moderna Inc (Symbol: MRNA) entered into oversold territory, hitting an RSI reading of 29.3, after changing hands as low as $53.41 per share. By comparison ...

The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza ...

Below is a chart showing LLY's trailing twelve month trading history, with the $830 strike highlighted in orange: Moderna Inc (Symbol: MRNA) options are showing a volume of 68,653 contracts thus ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

U.S. stocks were higher after the close on Monday, as gains in the Consumer Goods, Financials and Industrials sectors led ...

The upcoming report from Moderna (MRNA) is expected to reveal quarterly loss of $1.91 per share, indicating a decline of 37.4% compared to the year-ago period. Analysts forecast revenues of $1.25 ...

Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), ...